Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00940225 · ClinicalTrials.gov registry record · Phase 2
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Phase 2 study of Cancer and Solid Tumors, sponsored by Exelixis.
- Completed
- Registry status
- Phase 2
- Development phase
- 730
- Enrollment target
- 20
- Study locations
NCT00940225: Completed Phase 2 study of Cancer and Solid Tumors, sponsored by Exelixis.
NCT00940225 is a Phase 2 study of Cancer and Solid Tumors that has completed, run by Exelixis. The registered enrollment target is 730 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00940225, a Phase 2 study of Cancer and Solid Tumors, has completed, sponsored by Exelixis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 730 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2 study to evaluate the efficacy and safety of cabozantinib (XL184) in subjects with selected advanced tumor types.
Primary Outcome
Objective response rate (ORR) per modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.0 per investigator The analysis of ORR in the RDT Cohorts were defined as the proportion of subjects with a best overall response of confirmed complete response (CR) or partial response (PR) per mRECIST 1.0 during the 12-week Lead-In Stage. In the NRE Ovarian Cohort, mRECIST 1.1 was used. ORR for the NRE CRPC Cohorts was not a primary objective and is therefore not captured in the table
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cabozantinib
Study Locations (20)
California
- University of California Davis Cancer Center - Sacramento
- University of California, San Francisco - San Francisco
- Stanford University Medical Center - Stanford
Missouri
- University of Missouri Health Care - Columbia
- Kansas City Cancer Center - Lee's Summit
- Midwest Hematology Oncology Consultants - St Louis
Florida
- Florida Cancer Specialists - Fort Myers
- Mount Sinai Comprehensive Cancer Center - Miami Beach
Michigan
- University of Michigan Health System - Ann Arbor
- Wayne State University - Detroit
New York
- NYU Clinical Cancer Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Arizona
- Pinnacle Oncology of Arizona - Scottsdale
Colorado
- Rocky Mountain Cancer Centers - Denver
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 730 participants |
| Start Date | 2009-09 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
What the finished NCT00940225 record still lists
NCT00940225 is an interventional study that assigns participants to a tested intervention. The registered 730 participants enrollment target is mid-sized for trials with a published cap, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (79% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00940225 names 20 study sites across 13 states, led by California, Missouri, Florida.
Frequently Asked Questions
What is clinical trial NCT00940225 about?
NCT00940225 is a clinical study titled "Study of Cabozantinib (XL184) in Adults With Advanced Malignancies". This is a Phase 2 study to evaluate the efficacy and safety of cabozantinib (XL184) in subjects with selected advanced tumor types.
What is the current status of trial NCT00940225?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 730 participants. The study started on 2009-09. Estimated completion is 2014-06.
What conditions does trial NCT00940225 study?
This clinical trial studies the following conditions: Cancer, Solid Tumors.
What interventions are being tested in trial NCT00940225?
The interventions under investigation include: Placebo (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT00940225?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00940225 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00940225's enrollment target sits among peer trials
730 97th of 615 higher than 519 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03232918 · 730 participants · Phase 4
Oxytocin and Fetal Heart Rate Changes
- NCT05548283 · 730 participants · Phase 4
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
- NCT07312162 · 730 participants
Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots
- NCT05065216 · 728 participants · Phase 2
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia